Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Genet Metab ; 110(3): 319-28, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23856419

ABSTRACT

Mucopolysaccharidosis VII (MPS VII) is due to the deficient activity of ß-glucuronidase (GUSB) and results in the accumulation of glycosaminoglycans (GAGs) in lysosomes and multisystemic disease with cardiovascular manifestations. The goal here was to determine the pathogenesis of mitral valve (MV) disease in MPS VII dogs. Untreated MPS VII dogs had a marked reduction in the histochemical signal for structurally-intact collagen in the MV at 6 months of age, when mitral regurgitation had developed. Electron microscopy demonstrated that collagen fibrils were of normal diameter, but failed to align into large parallel arrays. mRNA analysis demonstrated a modest reduction in the expression of genes that encode collagen or collagen-associated proteins such as the proteoglycan decorin which helps collagen fibrils assemble, and a marked increase for genes that encode proteases such as cathepsins. Indeed, enzyme activity for cathepsin B (CtsB) was 19-fold normal. MPS VII dogs that received neonatal intravenous injection of a gamma retroviral vector had an improved signal for structurally-intact collagen, and reduced CtsB activity relative to that seen in untreated MPS VII dogs. We conclude that MR in untreated MPS VII dogs was likely due to abnormalities in MV collagen structure. This could be due to upregulation of enzymes that degrade collagen or collagen-associated proteins, to the accumulation of GAGs that compete with proteoglycans such as decorin for binding to collagen, or to other causes. Further delineation of the etiology of abnormal collagen structure may lead to treatments that improve biomechanical properties of the MV and other tissues.


Subject(s)
Heart Valve Diseases/etiology , Mitral Valve/pathology , Mucopolysaccharidosis VII/complications , Animals , Chordae Tendineae/metabolism , Collagen/metabolism , Dogs , Extracellular Matrix/genetics , Extracellular Matrix/metabolism , Female , Glycosaminoglycans/metabolism , Heart Valve Diseases/metabolism , Male , Mitral Valve/metabolism , Mucopolysaccharidosis VII/metabolism , Peptide Hydrolases/genetics , Peptide Hydrolases/metabolism , Signal Transduction
2.
Mol Genet Metab ; 110(3): 311-8, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23860311

ABSTRACT

Mucopolysaccharidosis VII (MPS VII) is due to deficient activity of the lysosomal enzyme ß-glucuronidase (GUSB) and results in the accumulation of glycosaminoglycans (GAGs). This study determined the long-term effect of neonatal intravenous injection of a gamma retroviral vector (RV) on cardiac valve disease in MPS VII dogs. Transduced hepatocytes secreted GUSB into the blood for up to 11 years at levels similar to or greater than those achieved with enzyme replacement therapy (ERT). Valve regurgitation and thickening were scored from 0 (normal) to +4 (severely abnormal). At 1 year, untreated MPS VII dogs had mitral regurgitation, mitral valve thickening, aortic regurgitation, and aortic valve thickening scores of 2.3 ± 0.7, 2.3 ± 0.6, 1.8 ± 0.5, and 1.6 ± 0.7, respectively, which were higher than the values of 0.6 ± 0.1, 0.1 ± 0.4, 0.3 ± 0.8, and 0.1 ± 0.4, respectively, in treated MPS VII dogs. Treated MPS VII dogs maintained low aortic regurgitation and aortic valve thickening scores in their lifetime. Although mitral regurgitation and mitral valve thickening scores increased to 2.0 at ≥ 8 years of age in the treated MPS VII dogs, older normal dogs from the colony had similar scores, making it difficult to assess mitral valve disease. Older treated dogs had calcification within the mitral and the aortic valve annulus, while GUSB staining demonstrated enzyme activity within the mitral valve. We conclude that neonatal RV-mediated gene therapy reduced cardiac valve disease in MPS VII dogs for up to 11 years, and propose that neonatal initiation of ERT should have a similar effect.


Subject(s)
Gammaretrovirus/genetics , Genetic Therapy , Genetic Vectors/genetics , Heart Valve Diseases/etiology , Heart Valve Diseases/therapy , Mucopolysaccharidosis VII/complications , Mucopolysaccharidosis VII/genetics , Animals , Animals, Newborn , Aortic Valve/diagnostic imaging , Aortic Valve/pathology , Disease Models, Animal , Dogs , Echocardiography , Female , Glucuronidase/genetics , Glucuronidase/metabolism , Heart Valve Diseases/diagnostic imaging , Male , Mitral Valve/diagnostic imaging , Mitral Valve/pathology
3.
Mol Genet Metab ; 99(4): 396-407, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20044292

ABSTRACT

Mucopolysaccharidosis I (MPS I) and MPS VII are due to loss-of-function mutations within the genes that encode the lysosomal enzymes alpha-l-iduronidase and beta-glucuronidase, respectively, and result in accumulation of glycosaminoglycans and multisystemic disease. Both disorders are associated with elastin fragmentation and dilatation of the aorta. Here, the pathogenesis and effect of gene therapy on aortic disease in canine models of MPS was evaluated. We found that cathepsin S is upregulated at the mRNA and enzyme activity level, while matrix metalloproteinase 12 (MMP-12) is upregulated at the mRNA level, in aortas from untreated MPS I and MPS VII dogs. Both of these proteases can degrade elastin. In addition, mRNA levels for the interleukin 6-like cytokine oncostatin M were increased in MPS I and MPS VII dog aortas, while mRNA for tumor necrosis factor alpha and toll-like receptor 4 were increased in MPS VII dog aortas. These cytokines could contribute to upregulation of the elastases. Neonatal intravenous injection of a retroviral vector expressing beta-glucuronidase to MPS VII dogs reduced RNA levels of cathepsin S and MMP-12 and aortic dilatation was delayed, albeit dilatation developed at late times after gene therapy. A post-mortem aorta from a patient with MPS VII also exhibited elastin fragmentation. We conclude that aortic dilatation in MPS I and MPS VII dogs is likely due to degradation of elastin by cathepsin S and/or MMP-12. Inhibitors of these enzymes or these cytokine-induced signal transduction pathways might reduce aortic disease in patients with MPS.


Subject(s)
Aorta/enzymology , Dog Diseases/enzymology , Mucopolysaccharidosis I/enzymology , Mucopolysaccharidosis I/veterinary , Mucopolysaccharidosis VII/enzymology , Pancreatic Elastase/metabolism , Up-Regulation , Animals , Aortic Diseases/complications , Cathepsins/metabolism , Dogs , Elastin/metabolism , Humans , Male , Matrix Metalloproteinase 12/metabolism , Mucopolysaccharidosis VII/veterinary , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...